Brentuximab vedotin

BNF:
8.1.5
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

RED:

  • NICE TA478: - for treating relapsed or refractory systemic anaplastic large cell lymphoma.  (NHSE commissioned).  (Decision date - November 2017).
  • NICE TA524: for treating CD30-positive Hodgkin lymphoma.  (Replaces NICE TA446).  (NHSE commissioned).  (Decision date - July 2018).
  • NICE TA577: for treating CD30-positive cutaneous T-cell lymphoma.  (NHSE commissioned).  (Decision date - May 2019).
  • NICE TA641: in combination for untreated systemic anaplastic large cell lymphoma.  (NHSE commissioned).  (Decision date - September 2020).

Do Not Prescribe (DNP):

  • NICE TA594: untreated advanced Hodgkin lymphoma.  (Terminated appraisal).  (Decision date - September 2019).

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app